SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves selloff is being discussed alongside concerns about its heavy debt load, rising borrowing costs and whether AI demand and contract backlog can support its financing needs, with HSBCs bearish assessment adding to the pressure. Traders are split between viewing the balance-sheet risks and insider selling as reasons for further downside and arguing that strong demand, the backlog and Nvidia ties make the drop a buying opportunity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Lilly is drawing attention after breaking to a new high, with traders linking the rally to European regulatory backing for its Foundayo obesity pill and broader optimism about its GLP-1 business. Bulls are celebrating the breakout and healthcares defensive appeal, while skeptics point to possible profit-taking, competition from Novo and the upcoming earnings report.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to record lows is fueling a heavily bearish conversation, with traders tying its political-proxy appeal to concerns about Trumps approval and the midterms, while questioning the companys business traction. A smaller bullish contingent sees a possible trading bounce and points to the pending TAE fusion deal as a potential pivot.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers rally to a 52-week high is driving discussion, with traders citing momentum and rotation into defensive, dividend-paying pharma amid broader market weakness. Bulls see a potential breakout, while skeptics point to resistance and say a fresh company-specific catalyst is needed.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as traders react to elevated crude prices and fears that Middle East shipping or energy-infrastructure attacks could disrupt supply, while weighing possible diplomacy and Russian supply relief. The community is split between bulls focused on geopolitical risk and bears expecting the risk premium to fade, with some also warning that contract-roll effects and an extended run may amplify volatility.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Rapport Therapeutics Inc.

Rapport Therapeutics Inc

Rapports Phase 2 RAP-219 trial in bipolar mania met its primary and secondary endpoints, drawing attention to the drugs potential but also to concerns about modest symptom improvement, agitation-related side effects, and discontinuations. Traders are divided, with some viewing the move as a fading bounce and adding shorts while others point to bullish analyst commentary.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor is drawing attention after strong Q3 results and an upbeat outlook, with AI-related demand and growing Vertical Power Delivery royalty revenue reinforcing the growth story. Traders are weighing that strength against questions about one-time royalty catch-up payments, production capacity, and the earnings-per-share miss, contributing to a volatile reaction.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GM is selling off despite a third-quarter earnings and revenue beat and a new multiyear buyback, as traders focus on the narrowed profit outlook with its midpoint unchanged and declining U.S. sales and market share. Some see the decline as a buying opportunity given cash generation and capital returns, while others argue the outlook failed to justify the valuation.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after quarterly results beat expectations and the company raised its full-year outlook, citing strong aerospace and defense demand and a record backlog. Traders broadly praised the results, while some questioned why the share-price reaction was muted.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces quarterly results beat expectations and the company raised its outlook, but shares fell as traders weighed rising costs, weaker cash flow and a loss in its insurance business. The reaction has split the community between buyers calling the selloff unjustified after a strong report and bears focused on the cost pressures and weak price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers

Celularity (NASDAQ:CELU) stock moved upwards by 134.0% to $2.06 during Thursday's regular session. The company's market cap stands at $25.0 million.
Propanc Biopharma (NASDAQ:PPCB) stock increased byread more...

Crude Oil Moves Higher; Dollar General Shares Gain After Upbeat Q2 Earnings

U.S. stocks traded higher, Dow up 0.20%, NASDAQ up 1.05%, S&P 500 up 0.47%. Tech shares jumped 2.4% while consumer staples fell 1%. Dollar General gained 5% on strong earnings. Propanc Biopharma soared 157%. Okta and Veeva Systems also rose. Build-A-Bear Workshop and Healthequity fell on earnings...

Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results

Propanc Biopharma reports strong preclinical data from pancreatic cancer drug, PRP, showing over 90% tumor inhibition and extended survival.read more...

Mega Movers

The market is getting a fresh reminder that the biggest opportunities are increasingly being built around AI, cybersecurity, advanced medicine and the infrastructure required to commercialize them. Propanc Biopharma (NASDAQ:PPCB), Celularity (NASDAQ:CELU), NeOnc Technologies (NASDAQ:NTHI), Salesforce (NYSE:CRM), CrowdStrike (NASDAQ:CRWD), and Okta (NASDAQ:OKTA).

Nasdaq Surges 200 Points; Nvidia Posts Upbeat Q2 Results

US stocks traded higher with Nasdaq up 200 points. Dow down 0.01%, Nasdaq up 0.77%, and S&P 500 up 0.27%. Tech shares rose 2.2% while consumer staples fell 1.1%. Nvidia reported strong earnings. Propanc Biopharma up 211%, VolitionRX up 86%, Mint Incorporation up 74%, Alpha Modus down 25%, Change...

Propanc’s PRP Just Entered a New Cancer Conversation

Propanc Biopharma (NASDAQ:PPCB) is moving into a potentially important moment for its lead cancer candidate PRP, as new preclinical data arrive just as the pancreatic-cancer treatment landscape is undergoing a major transformation.

PPCB Stock Surges Over 200% Just Days After Implementing Reverse Share Split – What’s Driving Today’s Smashing Rally?

Equity

Propanc Biopharma announced the approval of a share buyback program worth up to $5 million.

Clinical-Stage Biotech Rockets 308% After $5M Buyback and Phase 1 Cancer-Trial Path

For early-stage life sciences plays, deploying capital into a buyback program serves to validate management's view of a company's pipeline value. Today, an international developer focused on treating metastatic solid-tumor cancers triggered a triple-digit single-session market rally following a dual operational and capital-allocation update.
Propanc Biopharma, Inc. (Nasdaq: PPCB) surged in Wednesday trading announcing its board of directors approved a $5.0M common-stock repurchase program. Management explicitly framed the capital-return initiative alongside core execution milestones for ...

Biotech And AI Stocks Deliver Fresh Catalysts, as Investors Swarm into Growth Stories

Today's market action highlighted a familiar theme across the small-cap landscape: investors continue searching for transformative growth stories amid a market increasingly driven by company-specific catalysts. $TGNT, $TOVX, $MGNI, $PPCB, $MASK

This account has been verified as an official PPCB representative.

Verified Account

Propanc Biopharma Responder

Propanc Biopharma, Inc. is a development-stage healthcare company, which engages in the research and development of cancer treatments. The firm focuses on the treatment of pancreatic, ovarian, and colorectal cancer. It offers its product pipeline, including PRP and POP1. The company was founded by James Nathanielsz and Julian Kenyon on October 15, 2007 and is headquartered in Camberwell, Australia.

Propanc Biopharma Inc

Bullish Sentiment

<ul class="summary-bullets"><li>The management said the current stock price does not fully reflect the company’s underlying value and long-term potential.</li><li>Propanc had implemented a 1-for-25 reverse stock split on May 18.</li><li>The biotech firm is currently working on two cancer research programs.</li></ul>Shares of Propanc Biopharma (PPCB) ripped past 200% on Thursday, clocking their biggest single-day gains since the company implemented a reverse stock split last month, as investors cheered a share repurchase program that authorizes it to buy back up to $5 million of its common stock.At the time of writing, the company’s market cap was around $4 million.The biotech firm said it may repurchase shares from time to time, citing its belief that the current stock price does not fully reflect the company’s underlying value and long-term potential.“Repurchases will be considered when we believe the market price meaningfully understates intrinsic value and when buybacks compete favorably relative to other uses of capital. We believe we are approaching such a position,” said James Nathanielsz, Propanc’s chief executive officer.<h2 class="st-heading-2">PPCB’s Reverse Stock Split Took Effect On May 18</h2>The latest development comes less than a month after Propanc implemented a 1-for-25 reverse stock split. As a result, the company's outstanding share count was reduced from about 57 million to roughly 2.3 million.The reverse stock split was implemented to restore compliance with Nasdaq’s $1 minimum bid price requirement and to support growth plans, Nathanielsz said.<h2 class="st-heading-2">What’s In PPCB’s Pipeline?</h2>Propanc Biopharma is working on two cancer research programs. Earlier this year, it partnered with Germany-based FyoniBio to develop and validate a pharmacokinetics assay for its Phase 1b first-in-human study of its lead cancer therapy candidate. The assay will help measure drug levels and activity in patients with advanced solid tumors.Separately, Propanc entered into a multi-year research collaboration with the Universities of Jaén and Granada in Spain to evaluate an anti-aging compound and conduct additional studies to support the company’s fibrosis- and cancer-related patent applications.<h2 class="st-heading-2">Retail’s Take On PPCB’s Super Rally</h2>Retail sentiment surrounding <a href="https://stocktwits.com/symbol/PPCB">PPCB</a> on Stocktwits turned ‘extremely bullish’ from ‘neutral,’ amid ‘extremely high’ message volumes.One user said the stock’s momentum could last for a couple of days and expects support at around $4.<stembedurl>https://stocktwits.com/DeltaVariant/message/656140841</stembedurl>However, another user called it a “high-risk bet on short-term retail momentum.”<stembedurl>https://stocktwits.com/Zipcash/message/656137996</stembedurl>Read also: <a href="https://stocktwits.com/news-articles/equity/markets/iran-targets-elon-musk-companies-spacex-in-focus/cZKTuuJR720">SpaceX Assets Among Iran’s Military Targets, Says State Media – Accuses Elon Musk-Related Businesses Of Supporting ‘War Crimes’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$0.3216
Prev Close	$0.317
Open	$0.3077
Dividend Yield	0.00%
50-Day Moving Average	$0.8372
Beta	0.00
Avg. Volume	321,837.55
PE Ratio	-0.01

52-Week High	$41.00
52-Week Low	$0.3109
Market Capitalization	$3.27M
EPS (Annual)	-$17.62
Price to Book	0.11
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

PPCB Fundamentals